Trials / Completed
CompletedNCT02215616
A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod
A Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/Day) as Treatment in Patients With Huntington's Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 352 (actual)
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc. · Industry
- Sex
- All
- Age
- 21 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to assess the efficacy of laquinimod as treatment in participants with HD after 52 weeks using the Unified Huntington's Disease Rating Scale Total Motor Score (UHDRS-TMS or TMS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Laquinimod | Laquinimod capsules will be administered as per the dose and schedule specified in the respective arms. |
| DRUG | Placebo | Matching laquinimod placebo will be administered as per the schedule specified in the respective arms. |
Timeline
- Start date
- 2014-10-28
- Primary completion
- 2018-06-19
- Completion
- 2018-06-19
- First posted
- 2014-08-13
- Last updated
- 2020-05-04
- Results posted
- 2019-06-19
Locations
53 sites across 10 countries: United States, Canada, Czechia, Germany, Italy, Netherlands, Portugal, Russia, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02215616. Inclusion in this directory is not an endorsement.